Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Plerixafor for Endometrial Disorders (AS, AE, RIF)
NCT05343572Phase 1Recruiting
- Start
- Nov 2023
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of plerixafor in Asherman's syndrome (AS), Atrophic endometrium and Recurrent Implantation Failure (RIF). Primary endpoints: Change in endometrial thickness at 24 months and Implantation rates at 24 months. Started Nov 2023; status: recruiting.
02
Drugs
plerixafor
03
Conditions
Asherman's syndrome (AS)Atrophic endometriumRecurrent Implantation Failure (RIF)
Beyond the preview
Go deeper on NCT05343572.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05343572.